Business Wire

IL-NIELSENIQ

13.5.2024 18:20:35 CEST | Business Wire | Press release

Share
NielsenIQ launches GenAI-based tool NIQ Ask Arthur into NIQ Discover empowering users to unlock the power of data

NielsenIQ (NIQ), the world leader in measurement and data analytics, is excited to announce that ‘NIQ Ask Arthur’- a groundbreaking GenAI-driven tool—has been integrated into NIQ Discover. This transformative solution offers AI-guided global search and personalized recommendations, streamlining data analysis and facilitating informed decision-making. Launching “NIQ Ask Arthur” marks an important milestone for NIQ Labs. Positioned as an innovation powerhouse, NIQ Labs is ready to accelerate the future of innovation by solving client problems and uncovering new pathways to growth. Coupled with investments, NIQ Labs taps into an extensive array of data assets, employing intuitive business intelligence tools and predictive analytics driven by generative AI (GenAI) and authoritative data science pioneering the next era of inventive products.

With conversational AI features, ‘NIQ Ask Arthur’ empowers users to delve deeper into datasets, revolutionizing data-driven choices and showcasing NielsenIQ's commitment to cutting-edge analytics.

NIQ Discover, a state-of-the-art data visualization solution, accelerates access to insights for CPG manufacturers and retailers. It creates fresh, user-friendly pathways to insights, leveraging the power of on-demand data across multiple data sets. NIQ Discover is designed to help CPG manufacturers and retailers get meaningful insights faster, and measure and track what’s most important to their business within a single, centralized platform.

NIQ Ask Arthur in NIQ Discover enables enhanced insights discovery, so users can efficiently uncover valuable information, enriching the brand story and democratizing data access. Current and new users can uncover meaningful information, trends, and patterns that may otherwise go unnoticed, leading them to the most relevant areas of analysis. At NIQ we provide the Full View™, and we maintain the highest standard of data accuracy and quality. GenAI will help NIQ Discover users decipher diverse formats and tackle complex business questions.

“The vision of leveraging AI to assist in data analysis and storytelling is incredibly powerful. Democratizing access to data and analytics is crucial in helping users make informed decisions and drive innovation. ‘NIQ Ask Arthur’ unlocks the power of analytics on the Discover platform,” says Troy Treangen, Chief Product Officer, NIQ.

NIQ Ask Arthur in Discover enables users to save time by proactively suggesting insights and simplifying data navigation through a seamless, conversational AI-powered experience.

With NIQ’s investment in the cutting edge NIQ Discover platform, combined with our diverse data types and deep industry expertise, NIQ Ask Arthur delivers unparalleled value to clients.

NIQ is best positioned to understand data and the business questions that help brands unravel their story. The company’s agility and rapid deployment strategies have facilitated remarkable technological advancement. In the past year, the NIQ Discover platform witnessed extraordinary growth, surging from 2,500 users in January 2023 to an impressive 40,000 across 71 countries today, showcasing the vast scale of NIQ’s technological expansion. This ability to rapidly deploy technology, enhance user engagement, and establish a global presence underscores NIQ’s unparalleled agility and innovation in the tech industry. These advancements facilitate accelerated insights across diverse industries, channels, and products, driving speed-to-insight at an unprecedented scale to deliver the Full View™.

About NIQ

NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in 95+ countries representing 97% of the world’s GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513168921/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye